Literature DB >> 27965306

Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial.

Lea Lowenfeld1, Rosemarie Mick2, Jashodeep Datta1, Shuwen Xu1, Elizabeth Fitzpatrick1, Carla S Fisher1, Kevin R Fox3, Angela DeMichele3, Paul J Zhang4, Susan P Weinstein5, Robert E Roses1, Brian J Czerniecki6.   

Abstract

Purpose: Vaccination with HER2 peptide-pulsed DC1s stimulates a HER2-specific T-cell response. This randomized trial aimed to establish safety and evaluate immune and clinical responses to vaccination via intralesional (IL), intranodal (IN), or both intralesional and intranodal (ILN) injection.Experimental Design: Fifty-four HER2pos patients [42 pure ductal carcinoma in situ (DCIS), 12 early invasive breast cancer (IBC)] were enrolled in a neoadjuvant HER2 peptide-pulsed DC1 vaccine trial. Patients were randomized to IL (n = 19), IN (n = 19), or ILN (n = 16) injection. Immune responses were measured in peripheral blood and sentinel lymph nodes by ELISPOT or in vitro sensitization assay. Pathologic response was assessed in resected surgical specimens.
Results: Vaccination by all injection routes was well tolerated. There was no significant difference in immune response rates by vaccination route (IL 84.2% vs. IN 89.5% vs. ILN 66.7%; P = 0.30). The pathologic complete response (pCR) rate was higher in DCIS patients compared with IBC patients (28.6% vs. 8.3%). DCIS patients who achieved pCR (n = 12) and who did not achieve pCR (n = 30) had similar peripheral blood anti-HER2 immune responses. All patients who achieved pCR had an anti-HER2 CD4 immune response in the sentinel lymph node, and the quantified response was higher by response repertoire (P = 0.03) and cumulative response (P = 0.04).Conclusions: Anti-HER2 DC1 vaccination is a safe and immunogenic treatment to induce tumor-specific T-cell responses in HER2pos patients; immune and clinical responses were similar independent of vaccination route. The immune response in the sentinel lymph nodes, rather than in the peripheral blood, may serve as an endpoint more reflective of antitumor activity. Clin Cancer Res; 23(12); 2961-71. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27965306     DOI: 10.1158/1078-0432.CCR-16-1924

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  41 in total

Review 1.  Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond.

Authors:  Ricardo L B Costa; Brian J Czerniecki
Journal:  NPJ Breast Cancer       Date:  2020-03-12

Review 2.  Vaccines targeting helper T cells for cancer immunotherapy.

Authors:  Marit Melssen; Craig L Slingluff
Journal:  Curr Opin Immunol       Date:  2017-07-26       Impact factor: 7.486

Review 3.  Trial watch: dendritic cell vaccination for cancer immunotherapy.

Authors:  Jenny Sprooten; Jolien Ceusters; An Coosemans; Patrizia Agostinis; Steven De Vleeschouwer; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi; Abhishek D Garg
Journal:  Oncoimmunology       Date:  2019-07-18       Impact factor: 8.110

Review 4.  Therapeutic cancer vaccine: building the future from lessons of the past.

Authors:  T Tran; C Blanc; C Granier; A Saldmann; C Tanchot; Eric Tartour
Journal:  Semin Immunopathol       Date:  2018-07-05       Impact factor: 9.623

5.  Heterologous Prime-Boost Enhances the Antitumor Immune Response Elicited by Plant-Virus-Based Cancer Vaccine.

Authors:  Hui Cai; Sourabh Shukla; Chao Wang; Hema Masarapu; Nicole F Steinmetz
Journal:  J Am Chem Soc       Date:  2019-04-16       Impact factor: 15.419

Review 6.  Immunological Landscape of HER-2 Positive Breast Cancer.

Authors:  Santiago Moragon; Cristina Hernando; Maria Teresa Martinez-Martinez; Marta Tapia; Belen Ortega-Morillo; Ana Lluch; Begoña Bermejo; Juan Miguel Cejalvo
Journal:  Cancers (Basel)       Date:  2022-06-28       Impact factor: 6.575

Review 7.  Breaking through to the Other Side: Microenvironment Contributions to DCIS Initiation and Progression.

Authors:  Andrew C Nelson; Heather L Machado; Kathryn L Schwertfeger
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-08-31       Impact factor: 2.673

Review 8.  Clinical Trials for Ductal Carcinoma In Situ of the Breast.

Authors:  Michelle S Han; Seema A Khan
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-09-11       Impact factor: 2.673

9.  Immunotherapy for Breast Cancer: Current and Future Strategies.

Authors:  Austin D Williams; Kyle K Payne; Avery D Posey; Christine Hill; Jose Conejo-Garcia; Carl H June; Julia Tchou
Journal:  Curr Surg Rep       Date:  2017-10-10

10.  Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial.

Authors:  Melody A Cobleigh; Stewart J Anderson; Kalliopi P Siziopikou; Douglas W Arthur; Rachel Rabinovitch; Thomas B Julian; David S Parda; Samantha A Seaward; Dennis L Carter; Janice A Lyons; Melissa S Dillmon; Gustav C Magrinat; Vivek S Kavadi; Allison M Zibelli; Lavanya Tiriveedhi; Matthew L Hill; Marianne K Melnik; Sushil Beriwal; Eleftherios P Mamounas; Norman Wolmark
Journal:  J Clin Oncol       Date:  2021-03-19       Impact factor: 50.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.